This bill expands New Jersey's regulation of health care service firms by requiring employment agencies and other entities that place individuals in personal residences to register as Health Care Service Firms if they provide companion, health care, or personal care services to people with disabilities or those age 60 and older. The law mandates that registered firms obtain accreditation from a recognized body within 12 months and submit annual financial statements to the Division of Consumer Affairs, with larger firms required to undergo external audits every three years or annually if gross income exceeds $10 million. Smaller firms receiving less than $500,000 in Medicaid Personal Care Assistance services must submit annual reports detailing insurance coverages and internal management practices instead of full audits. These provisions apply regardless of whether the firm uses direct employment, online platforms, or other business models to connect service providers with clients.
This bill (A 3434) requires New Jersey dialysis centers to allow patients receiving treatment to be accompanied by a designated support person who can assist with communication, mobility, and care decisions. It directly affects dialysis patients and the centers providing their treatment. Centers must create and display clear written policies for support person access, implement reasonable health/safety rules (without unnecessary restrictions), and train staff on these policies. The New Jersey Department of Health will enforce the law, investigate complaints about denied access, and impose penalties for non-compliance. The law takes effect immediately upon passage.
This bill requires health insurance plans in New Jersey to continue covering adult children with disabilities who are 26 or older, provided they cannot work due to a physical or intellectual disability and are financially dependent on their parent. It amends existing law to extend coverage beyond the standard age limit of 26 for this specific group, ensuring they maintain health insurance through their parent's plan. The bill prohibits denial of coverage based on factors like marriage, having a child, or school status, which commonly affected young adults with disabilities. This change directly impacts young adults with disabilities in New Jersey who would otherwise lose coverage at age 26 but meet the eligibility criteria.
This bill permanently requires New Jersey health insurance carriers to pay the same reimbursement rate for telemedicine and telehealth services as they do for in-person visits, provided the service is otherwise covered. It ensures patients face no higher deductibles, copays, or coinsurance for telehealth compared to in-person care. The law prohibits insurers from restricting where telehealth services can occur, limiting which technology platforms providers can use, or denying coverage for routine remote monitoring. It directly affects health insurance companies, healthcare providers offering telehealth, and patients receiving covered telehealth services. The policy change applies to all health benefits plans in New Jersey without time limits.
This bill would require New Jersey Medicaid to cover ovulation-enhancing drugs and related medical services without restrictions for beneficiaries experiencing infertility. It directly affects low-income New Jersey residents enrolled in Medicaid who seek infertility treatment. The key provision amends Medicaid law to explicitly include these services as a standard benefit, removing prior authorization requirements. This change would expand current coverage to ensure these treatments are accessible as routine care for eligible individuals.
This bill (A 964) creates a 15-member "Nursing Home Emergency Preparedness Study Commission" to analyze how New Jersey nursing homes respond to public health emergencies. The commission will examine nursing home environments, emergency policies, staffing levels, and funding needs during crises, and make recommendations to improve resident safety. It includes state health and human services officials, nursing home industry representatives (appointed by legislative leaders), and family members of residents (appointed by the Governor). The commission must submit a report to the Governor and Legislature within 12 months of its first meeting and then expire. This is a procedural study bill with no immediate policy changes, focusing on future recommendations.
This bill creates a statewide stockpile of essential medicines, vaccines, and medical supplies to be managed by New Jersey's Department of Health and State Office of Emergency Management. The stockpile, funded by state appropriations, will be used during emergencies like natural disasters, disease outbreaks, or public health crises. Key provisions require the state to establish distribution guidelines prioritizing healthcare providers in rural and medically underserved areas, with supplies managed through contracts that may include vendor-managed "virtually sequestered" inventories to prevent expiration. The bill mandates demand planning to determine stockpile contents and quantities based on emergency scenarios.
This bill expands New Jersey's existing requirement for health insurance plans to cover prostate cancer screenings without any out-of-pocket costs. It specifically requires coverage for annual screenings - including digital rectal exams and PSA tests - for men aged 50 and older (asymptomatic) and men aged 40 and older with a family history of prostate cancer or other risk factors. The law applies to most health insurance plans, including high-deductible plans where permitted by federal law, and mandates coverage "to the same extent as for any other medical condition." It does not alter existing coverage for other preventive services but ensures no cost-sharing (like deductibles or copays) applies to these specific screenings.
This bill exempts drug manufacturers and distributors from New Jersey's pharmacy licensing requirements when distributing dialysate drugs and devices used for home dialysis treatment of end-stage renal disease patients. It directly affects dialysis manufacturers, distributors, and patients receiving home dialysis, allowing them to bypass standard pharmacy licensing rules under six specific conditions. Key provisions include requiring FDA approval, direct delivery only upon physician orders, original sealed packaging, and mandatory weekly quality checks by a consultant pharmacist. The law ensures these products are handled safely while streamlining access for patients needing home dialysis.
This New Jersey bill creates a new crime called fertility fraud, which specifically targets licensed health care practitioners who knowingly use a patient's reproductive material without their written consent. Under the law, a practitioner commits this offense if they use their own sperm or eggs or the material of another person to cause a pregnancy without the patient's informed agreement. If convicted of this third-degree crime, the individual faces up to five years in prison, a fine of $15,000, and the mandatory permanent revocation of their medical license. Additionally, the legislation extends the statute of limitations for prosecuting this specific offense to 20 years from the date of the treatment or 10 years from when the victim discovers the fraud, whichever is later.